Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

[1]  D. Giugliano,et al.  GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials , 2019, Diabetes, obesity & metabolism.

[2]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[3]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[4]  W. E. Sanabria,et al.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. , 2019, Lancet.

[5]  B. Zinman,et al.  Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[6]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[7]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[8]  K. Khunti,et al.  Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis , 2019, Diabetic medicine : a journal of the British Diabetic Association.

[9]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[10]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[11]  R. Holman,et al.  Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL , 2018, Diabetes Care.

[12]  M. Rizzo,et al.  GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[13]  D. Drucker.  The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications , 2018, Diabetes.

[14]  É. Hardy,et al.  DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone , 2018, Diabetes.

[15]  B. Ludvik,et al.  Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[16]  D. Bell,et al.  Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk , 2018, Diabetes Therapy.

[17]  J. McMurray,et al.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.

[18]  É. Hardy,et al.  Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study , 2018, Diabetes, obesity & metabolism.

[19]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[20]  V. Perkovic,et al.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. , 2015, The Cochrane database of systematic reviews.

[21]  S. Suissa.  Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? , 2017, Diabetes Care.

[22]  R. DeFronzo.  Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor , 2017, Diabetes, obesity & metabolism.

[23]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[24]  B. Zinman,et al.  Liraglutide and Renal Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[25]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[26]  D. Bell,et al.  Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Sequential or simultaneous start? , 2017, Diabetes, obesity & metabolism.

[27]  B. Staels.  Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. , 2017, The American journal of medicine.

[28]  Gaosi Xu,et al.  SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease , 2017, Cardiovascular Diabetology.

[29]  Neha J. Pagidipati,et al.  Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) , 2017, American heart journal.

[30]  A. Lammertsma,et al.  Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine , 2016, Cardiovascular Diabetology.

[31]  F. Saeed,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2017, The New England journal of medicine.

[32]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[33]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[34]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[35]  R. Vettor,et al.  SGLT2 Inhibitors and the Diabetic Kidney , 2016, Diabetes Care.

[36]  M. Pencina,et al.  Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. , 2016, American heart journal.

[37]  K. Mahaffey,et al.  Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[38]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[39]  R. Busch,et al.  SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[40]  M. Diamant,et al.  The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? , 2014, Nature Reviews Nephrology.

[41]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[42]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[43]  Marie Davidian,et al.  Doubly robust estimation of causal effects. , 2011, American journal of epidemiology.

[44]  James Lo,et al.  Scaling Roll Call Votes with wnominate in R , 2008 .

[45]  Peter C Austin,et al.  A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.

[46]  Peter C Austin,et al.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study , 2007, Statistics in medicine.

[47]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[49]  G M Raab,et al.  How to select covariates to include in the analysis of a clinical trial. , 2000, Controlled clinical trials.